Michael Oredsson President and CEO
Degree in International Business Administration from Lund University. Born 1960. Lives in Beddingestrand, Sweden. Employed since 2013. He was CEO of Probi AB 2007-2013. Former CEO of Biosignal in Australia, 2002-2007, and Nutripharma in Norway, 1999-2001. Before that he was responsible for building up Pharmacia’s OTC product division in Australia. He also held senior marketing positions at Nestlé and Mars Inc in Sweden, Germany and France.
Options: Employee options: 18,719
Stefan Ericsson Chief Financial Officer
MBA, Lund University. Born 1963. Lives in Lund, Sweden. Employed since 1998. Chief Financial Officer since 2016 and has previously served as Director Business Control. He was employed by the Swedish Tax Authority 1996-1997. Previously he worked as an auditor at PricewaterhouseCoopers 1990-1995.
Options: Employee options: 3,750
Björn Frendéus Chief Scientific Officer
Doctor of Immunology. Born 1973. Lives in Landskrona, Sweden. Employed since 2001. Graduated from the Swedish Foundation for Strategic Research funded Biomedicine programmes within the Infection & Vaccinology programme in 2001. Visiting Professor at University of Southampton.
Shareholding: 317,151 (own and affiliated holdings)
Options: Employee options: 6,000
Kristoffer Rudenholm Hansson Senior Vice President, Technical Operations
Master of Science in Chemical engineering. Born 1974. Lives in Malmö Sweden. Employed since 2016 and responsible for process development and production of antibodies for clinical studies. He has more than 15 years’ experience from managing manufacturing of antibodies and other proteins for clinical use. Kristoffer has held a numerous positions within CMC Biologics A/S, DAKO A/S and Symphogen A/S.
Shareholding: 491,628 (whereof 148,176 in Sw. kapitalförsäkring)
Options: Stock options: 50,000
Anna Wickenberg Senior Vice President, Clinical Development
PhD in Medical Sciences, Immunology, and MSc in Molecular Biology. Born in 1974. Lives in Lund, Sweden. Employed since 2015 and responsible for the clinical development. She has 15 years of experience of leading clinical development projects from various positions at Teva Pharmaceuticals, NeuroSearch, and AstraZeneca. Most recently, Anna was responsible for the clinical development of new chemical entities in an orphan indication within CNS at Teva.
Shareholding: 231 348